Basic Information
| ID | DRAMP21236 |
| Sequence | WKRIVRRIWRWLR |
| Length | 13 |
| Name | FK13-a3 (Derived from FK13) |
| Source | Synthetic construct |
| Activity | Antimicrobial, Antibacterial, Anti-Gram+, Anti-Gram- |
| Pathogen | [Ref.28161291] Gram-positive bacteria : Bacillus subtilis(KCTC 3068)(MIC=2 μM), Staphylococcus epidermidis(KCTC 1917)(MIC=8 μM), Staphylococcus aureus(KCTC1621)(MIC=2 μM);##Gram-negative bacteria : Escherichia coli(KCTC 1682)(MIC=8 μM), Pseudomonas aeruginosa(KCTC 1637)(MIC=16 μM), Salmonella typhimurium(KCTC 1926)(MIC=4 μM) |
| Hemolytic Activity | [Ref.28161291] HC50=12.5 μM against human red blood cells |
| Cytotoxicity | [Ref.28161291] The cell viability of mouse macrophage RAW264.7 induced by FK13-a3 is 102.3%, 112.1%, 104.5%, 103.8%, 74.3% and 70.2% at peptide concentrations of 1.25, 2.5, 5, 10, 20 and 40 μM.## The cell viablity of human keratinocyte HaCaT induced by F |
| N-terminal Modification | Free |
| C-terminal Modification | Amidation |
| Linear/Cyclic/Branched | Linear |
| Uniprot |
|
| PDB |
|
| 3D View | |
|---|
| PDB Download | Download PDB Predicted by Alphafold2 |
|---|
| PubMed ID | 28161291 |
|---|